Literature DB >> 24667722

Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

C Criscitiello1, H A Azim2, E de Azambuja2, I T Rubio3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24667722     DOI： 10.1093/annonc/mdu034

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Authors:  Mehra Golshan; Constance T Cirrincione; William M Sikov; Lisa A Carey; Donald A Berry; Beth Overmoyer; Nora L Henry; George Somlo; Elisa Port; Harold J Burstein; Clifford Hudis; Eric Winer; David W Ollila
Journal:  Breast Cancer Res Treat       Date:  2016-10-04       Impact factor: 4.872

2.  Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Authors:  Mehra Golshan; Constance T Cirrincione; William M Sikov; Donald A Berry; Sara Jasinski; Tracey F Weisberg; George Somlo; Clifford Hudis; Eric Winer; David W Ollila
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

3.  Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis.

Authors:  Wenhua Ma; Fugang Zhao; Changpeng Zhou; Yongqian Zhang; Yingchun Zhao; Na Li; Peng Xie
Journal:  Onco Targets Ther       Date:  2019-01-03       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.